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(2) Patients with discrete mediastinal lymph node enlargement and 
contralateral FNA-demonstrated disease. 
FDG PET might provide information concerning the likelihood of 
involvement of the node as well as possible metastatic disease. The false 
positive rate for PET in the mediastinum is 15 to 20% and the false nega-
tive rate for patients with enlarged lymph nodes is 15 to 25%. Thus, per-
forming a needle aspiration technique either by EUS or EBUS is warrant-
ed. Given the false negative rate of 20 to 30%, ﬁnding a negative FNA 
should be followed by a mediastinoscopy. Patients with adenocarcinoma, 
large cell carcinoma or other histologies that are more likely metastatic, 
primary lesions larger than 2- 3 cm in largest dimension, centrally located 
tumors, tumors that have clinical N1 disease, those with FDG-PET SUV 
of > 7 or multiple abnormalities on PET or in those that have serum 
CEA level > 5 ng/L are all considered risk factors for potential N2 or N3 
disease and necessitate FNA and if negative, mediastinoscopy. In patients 
with peripheral primary tumors with no lymph node enlargement on CT, 
no other risk factors and no primary tumor FDG uptake (< 2.5) have a 
mediastinal disease prevalence of less than 3%.
In summary, patients who have enlarged or suspicious appearing medi-
astinal nodes on CT and/or those with FDG-PET or PET/CT uptake, an 
EUS and/or EBUS can be performed to conﬁrm the presence of disease 
rather than assuming malignant involvement. A thorough evaluation of 
the mediastinum should be performed. If metastatic disease is not found, 
then mediastinoscopy should be performed as the negative predictive 
value of FNA is insufﬁcient to rule out the presence of metastasis. If it 
is found, then induction therapy can be used. For those patients with a 
negative mediastinum on PET and CT and if the lesion is peripheral, 
in the outer third of the lung ﬁeld and the SUV of the primary is less 
than 2.5, then mediastinoscopy is unlikely to provide further helpful 
information. For more adenoscarcinomas and large cell cancers or cen-
tral or lesions larger than 4 cm or clinically N1 patients or in whom the 
SUV of the primary is larger than 7, then the prevalence of mediastinal 
involvement is higher, increasing the error of CT and PET. The negative 
predictive value in these cases is not sufﬁcient to eliminate the prob-
ability of disease in the mediastinum. Prospective trials evaluating the 
use of TEMLA should be performed to assess its ability in providing a 
survival advantage, but it does appear to provide superior staging infor-
mation. Future methods of genetic analysis of the primary tumor as well 
as genetic and marker analyses of the lymph nodes, bronchial washings, 
bone marrow and serum might provide greater prognostic information 
than simple histological examination of the mediastinal lymph nodes. If 
this is the case, mediastinoscopy might be unnecessary. 
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Lung cancer is the leading cause of cancer-related death in the U.S. 
and is projected to reach epidemic levels in the world during the 21st 
century. Chemotherapy has been largely ineffective in producing 
complete responses or cures in advanced disease so that over 85% of 
patients with lung cancer eventually succumb to the disease. Mortality 
could be reduced greatly by identifying persons at high risk for cancer 
and developing effective interventions to impede or reverse respiratory 
carcinogenesis. Key to the success of this strategy is the identiﬁcation 
of highly efﬁcacious preventive interventions and biomarkers that can 
both identify persons at the earliest stages of lung cancer development 
and monitor the efﬁcacy of interventions.
The silencing of genes through promoter hypermethylation is now rec-
ognized as a major and causal epigenetic event that occurs during lung 
cancer initiation and progression. Genes silenced by methylation are in-
volved in all aspects of normal cellular function that include control of 
cell proliferation, differentiation, and death. The involvement of gene 
methylation in carcinogenesis has led to studies focused on establishing 
the utility of methylation as a biomarker in screening for cancer risk, 
prevention, treatment, and prognosis. The development of the methyla-
tion-speciﬁc PCR (MSP) assay has facilitated these studies because it 
allows for the assay of methylation of speciﬁc genes in biological ﬂuids 
such as sputum where epithelial cells comprise only a fraction of the 
cellular content.
In a small proof-of-concept study, we detected p16 or MGMT gene 
promoter methylation in sputum up to 3 years prior to the diagnosis of 
SCC. The evaluation of cancer-free individuals who were at risk for 
lung cancer because of smoking and/or exposure to radon through ura-
nium mining revealed methylation of the p16 and MGMT genes in 15% 
and 25% of sputum samples, respectively. The most striking difference 
seen between lung cancer cases and controls was the detection of both 
methylated genes in 48% of sputum samples from cases but only in 3% 
of controls. These ﬁndings were the ﬁrst to suggest that aberrant gene 
methylation could be highly sensitive as molecular markers in popula-
tion-based screening for early detection of lung cancer.
The well-documented ﬁeld cancerization seen in lungs of smokers 
stemming from exposure of the entire respiratory tract to inhaled 
carcinogens within cigarette smoke presents an obstacle to the early 
detection of lung cancer. The generation of multiple, independently 
initiated pre-malignant lesions throughout the lungs of people with a 
long history of smoking likely accounts for detecting methylation of 
genes such as p16 that is inactivated in the earliest stages of pre-inva-
sive disease. We hypothesized that the use of promoter methylation as 
a biomarker for early detection of lung cancer would require a panel 
of genes whose presence in sputum confer a high enough sensitivity 
and speciﬁcity for distinguishing very advanced dysplasia or early lung 
cancer from the large “at risk” population. This hypothesis was tested 
in Speciﬁc Aim 1 of this project by conducting a nested case-con-
trol study of incident lung cancer cases from an extremely high-risk 
cohort (developed through the Colorado Lung SPORE) for evaluating 
promoter methylation of 14 genes in sputum. Controls (n=92) were 
cohort members matched to cases (n=98) by gender, age, and month of 
enrollment. The comparison of proximal sputum collected within 18 
months to > 18 months prior to diagnosis showed that the prevalence 
for methylation of gene promoters increased as the time to lung cancer 
diagnosis decreased. Six of 14 genes were associated with a > 50% 
increased lung cancer risk. The concomitant methylation of three or 
more of these six genes was associated with a 6.5-fold increased risk 
and a sensitivity and speciﬁcity of 64%. These studies have now been 
extended to evaluate new cases and controls as well as 20 additional 
candidate genes. These results will be presented. In addition, studies are 
ongoing to assess methylation of a gene panel in sputum obtained from 
the prevalent Stage I lung cancer case that is generally asymptomatic 
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for disease. These early stage lung cancers represent the cases whose 
identiﬁcation by the sputum-based methylation assay should beneﬁt 
from surgical resection. A case-control study is underway comparing 
methylation of an 8-gene panel in sputum from prevalent Stage I lung 
cancer cases to cancer free controls from the Lovelace Smokers cohort. 
Results indicate a sensitivity and speciﬁcity of 75% and 81%, respec-
tively for case identiﬁcation.
The identiﬁcation of genetic determinants for gene methylation could 
augment the gene methylation marker panel being developed for early 
detection. The hypothesis being tested is that diminished DNA repair 
capacity (DRC) is associated with increased methylation index detected 
in sputum from persons at risk for lung cancer. A nested, case-control 
study was conducted with members of the Lovelace Smokers Cohort. 
Cases and controls were deﬁned as cohort members with ≥ 3 or 0 genes 
methylated in sputum, respectively. The mutagen sensitivity assay was 
used to assess DRC. Lymphocytes from cases and controls were treated 
with bleomycin and chromosome breaks counted for 100 metaphases. 
A striking difference in DRC capacity (p < 0.001) between cases and 
controls was seen. Details of this study will be presented. These studies 
demonstrate a strong association between reduced repair capacity for 
double-strand DNA breaks and methylation index in sputum. Stud-
ies are in progress to identify speciﬁc gene haplotypes that predict for 
reduced DNA repair capacity and can add to the predictive power of 
our gene methylation panel for early detection of lung cancer. (Support 
by P50 CA58184 and U01 097356). 
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Molecular pathogenesis of lung cancer and its precursor lesions
From histological and biological perspectives, lung cancer is a com-
plex neoplasm. It can be divided into centrally arising tumors arising 
from the major bronchi and their divisions (squamous cell and small 
cell carcinomas) and peripherally arising adenocarcinomas (mainly 
adenocarcinomas and large cell carcinomas). In the bronchi the stem 
cell is thought to be the basal cell (for squamous cell carcinomas) and 
neuroendocrine cells (for small cell carcinomas). A peripheral airway 
cell has been identiﬁed in the mouse, and apparently is the common 
origin for clara cells and type 2 pneumocytes which are believed to be 
the precursor cells for bronchioles and alveoli respectively. 
Although the sequential preneoplastic changes have been deﬁned for 
centrally arising squamous carcinomas of the lung, they have been 
poorly documented for the other major forms of lung cancers, includ-
ing small cell lung carcinoma and adenocarcinomas. There are three 
main morphologic forms of preneoplastic lesions recognized in the 
lung: squamous dysplasias, atypical adenomatous hyperplasia (AAH), 
and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. 
However, these lesions account for the development of only a subset 
of lung cancers. Of interest, many changes associated with peripheral 
adenocarcinomas including KRAS and EGFR mutations have been 
demonstrated in AAH lesions. 
Some oncogenes such as EGFR may be activated by both mutations 
and/or ampliﬁcation. Preliminary studies indicate that mutation oc-
curs ﬁrst, followed by preferential ampliﬁcation of the mutant locus. 
Several studies have provided information regarding the molecular 
characterization of lung preneoplastic changes, especially for squamous 
cell carcinoma. These molecular changes have been detected in the 
histologically normal and abnormal respiratory epithelium of smokers. 
They indicate that molecular changes appear very early in the lengthy 
preneoplastic process, even before histologically detectable changes. 
Many histologically detected preneoplastic lesions are very small in 
size (1-5 mm). The small size and difﬁculties of identifying such le-
sions complicates their study. Fluorescence endoscopy aids the identiﬁ-
cation of such lesions, although most are ﬁxed in formalin and parafﬁn 
embedded, rendering molecular studies more difﬁcult. Approaches to 
the study of small preneoplastic lesions include microdissection of the 
epithelium, morphometric studies, allelic losses, gene mutations and 
ampliﬁcations, protein expression by immunostaing or in situ hybrid-
ization, gene expression at RNA or protein levels etc. The advent of 
CT screening approaches for early detection of lung cancer has led to 
the identiﬁcation of small ground glass opacity (GGO) type of lesions, 
some of which are AAH lesions. Thus these lesions can be biopsied or 
removed and information about their natural history obtained. 
The natural history of preneoplastic lesions is complex, and cancers 
may appear at sites previously biopsied and having minimal or no 
morphologic changes. Thus preneoplastic lesions may be indicators 
of smoke damaged epithelium with a greater propensity to progress to 
high grade lesions or invasive cancer, although the latter may not arise 
directly from morphologically identiﬁed lesions. Global approaches to 
studying preneoplasia include microarray expression data and com-
parative genomic hybridization. These techniques clearly demonstrate 
progressive changes from normal epithelium to dysplasia to CIS. CIS is 
also somewhat different from invasive squamous carcinomas. In addi-
tion, the bronchial epithelium of smokers and never smokers demon-
strate many changes. 
A novel method to study preneoplasia is the introduction of tumor as-
sociated genes into bronchial immortalized preneoplastic cell cultures. 
Bronchial epithelial cultures are immortalized by infection with CDK2 
and hTERT. Such cells are immortal but retain minimal cytogenetic and 
molecular changes. After introduction of oncogenes such as mutated 
KRAS or p53 knowcksown, or both, they develop morphologic and 
biologic features suggestive of preneoplastic respiratory epithelium. 
These altered cell lines demonstrate squamous dysplastic changes and 
the ability to invade the underlying matrix. However they usually lack 
tumorigenicity in mice. They appear to be useful models for studying 
preneoplasia.
Advances in biology are providing insights into the complex and 
lengthy preneoplastic process. These advances may impact on preven-
tion measures and identiﬁcation of individuals at greatly increased risk.
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